Answers are grounded in this paper and cite their sources.
Randomized trial reveals caplacizumab accelerates platelet count normalization and lowers recurrence in thrombotic thrombocytopenic purpura, indicating improved acute disease control.
Among patients with TTP, treatment with caplacizumab was associated with faster normalization of the platelet count; a lower incidence of a composite of TTP-related death, recurrence of TTP, or a thromboembolic event during the treatment period; and a lower rate of recurrence of TTP during the trial than placebo. (Funded by Ablynx; HERCULES ClinicalTrials.gov number, NCT02553317 .).
No takes yet. Share an insight, caveat, or question.
Scully et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: